View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Comment
March 1, 2018

Moderate growth in the multiple sclerosis market

Multiple sclerosis (MS) is an inflammatory autoimmune disease of the central nervous system (CNS) that leads to neurological disability.

By GlobalData Healthcare

Multiple sclerosis (MS) is an inflammatory autoimmune disease of the central nervous system (CNS) that leads to neurological disability. The MS therapeutics market has entered an exciting phase, with a wide range of treatment options and many promising late-stage pipeline drugs offering diverse mechanisms of action. GlobalData estimates that global sales for MS therapies in 2016 were approximately $21.9B, and expects them to grow to $22.5B in 2023.

Roche’s Ocrevus (ocrelizumab), which was approved in March 2017, making it the first drug to be approved for primary progressive MS, has been endorsed by key opinion leaders as being the best monoclonal antibody on the market due to showcasing its superior efficacy for first line MS treatment in its trials. Ocrevus has gained approval in the five major European markets (5EU: France, Germany, Italy, Spain, and UK), US, Canada, and Australia, and is forecast to have the highest sales in the MS market by 2023.

Furthermore, with a market crowded with treatment options, competitors will find it more difficult to differentiate themselves and gain control of market share. Other factors limiting the growth of the market include patent expiries of branded products, which will then expose those companies to generic competition, and pricing burdens on new entry drugs in a competitive market.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU